About OnDosis
OnDosis is a company based in Goteborg (Sweden) founded in 2017. OnDosis has raised $14.45 million across 4 funding rounds from investors including Astrazeneca, University of Gothenburg and European Union. OnDosis offers products and services including Dosage Manager and Connected Services. OnDosis operates in a competitive market with competitors including Lyndra, i2o Therapeutics, Biora Therapeutics, Cure Pharmaceutical and Cingulate, among others.
- Headquarter Goteborg, Sweden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ondosis Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.45 M (USD)
in 4 rounds
-
Latest Funding Round
$11.05 M (USD), Series B
May 25, 2021
-
Investors
Astrazeneca
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OnDosis
OnDosis offers a comprehensive portfolio of products and services, including Dosage Manager and Connected Services.
App for individualized medicine dosing and treatment optimization.
Suite linking patients, physicians, and data for better outcomes.
People of OnDosis
Unlock access to complete
Leadership Team
2 people
Software Development Team
1 people
Sales and Marketing
1 people
Supply Team
1 people
Unlock access to complete
Funding Insights of OnDosis
OnDosis has successfully raised a total of $14.45M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $11.05 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OnDosis
OnDosis has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, University of Gothenburg and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term value is created through active ownership in Nordic companies.
|
Locked | Locked | Locked | |
|
VC firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked |
Investor details for OnDosis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OnDosis
Investment portfolio details for OnDosis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OnDosis
Detailed financials for OnDosis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ondosis Comparisons
Peer comparison for OnDosis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OnDosis
OnDosis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lyndra, i2o Therapeutics, Biora Therapeutics, Cure Pharmaceutical and Cingulate, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Innovates long-acting oral therapies to simplify patient medication regimens.
|
|
| Locked | Locked | Locked |
Oral drug delivery solutions are provided via liquid technology platform.
|
|
| Locked | Locked | Locked |
Smart pills are developed for targeted gastrointestinal drug delivery.
|
|
| Locked | Locked | Locked |
Oral thin film-based drug delivery systems are developed.
|
|
| Locked | Locked | Locked |
Cingulate is focused on developing treatments for ADHD and anxiety.
|
Detailed competitors of OnDosis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ondosis
Complete news archive for OnDosis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OnDosis
OnDosis was founded in 2017 and raised its 1st funding round 2 years after it was founded.
OnDosis is headquartered in Goteborg, Sweden. It is registered at Goteborg, Vastra Gotaland, Sweden.
OnDosis is a funded company, having raised a total of $14.45M across 4 funding rounds to date.
OnDosis was founded in 2017 in Gothenburg, Sweden, within the health technology sector. Focus is placed on creating oral drug delivery systems, including the OnDosis 01 device, which enables precise, individualized dosing of oral medications in micro-unit volumes. This approach supports patients with conditions such as attention-deficithyperactivity disorder (ADHD) who face challenges in maintaining consistent medication schedules. Operations center on advancing drug administration technologies for improved patient compliance.
OnDosis's top competitors include i2o Therapeutics, Cingulate and Cure Pharmaceutical.
OnDosis offers Dosage Manager and Connected Services.
OnDosis has 6 investors. Key investors include Astrazeneca, University of Gothenburg, European Union, Aeternum Capital, and DIG Investment.